Myc proteins are transcriptional activators, but also repress transcription through initiator (Inr) elements. Repression requires the conserved Myc Box II, but the cis-acting element(s) required for c-myc autorepression have eluded definition. Since the gene has a candidate Inr at the P2 promoter, we tested whether Myc autorepression operates through the Inr/BoxII mechanism. Overexpression of c-Myc but not a Box II deletion mutation represses both c-myc P2 reporter genes and endogenous cmyc, as does Mxi1 expression. Only 45 nucleotides surrounding the P2 start suffice to mediate autorepression, but Myc and Mxi1 also downregulate P2 Inr mutations, suggesting other core promoter sequence requirements for autorepression. We tested the importance of conserved E2F sites, based on known Myc interaction with the pRb-related p107 and on the transrepressive effects of Rb family proteins. Myc, Mxi1, and p107 repress c-myc somewhat less well in the absence of E2F binding sites, while an E2F þ Inr double mutation is not repressed at all by these gene products. Further, Myc repression at the c-myc P2 core promoter is augmented by p107, but not by pRb or p130, nor by p107 lacking the conserved pocket domain. Our data suggest that Myc autorepression requires both the c-myc Inr and E2F sites in cis, as well as p107 in trans. Consistent with this, we found that retrovirally transduced c-Myc cannot downregulate endogenous c-myc in p107-null fibroblasts, and show evidence that both Myc and p107 are present in a complex assembled at the c-myc P2 core promoter.
Introduction
Changes in Myc abundance are tightly controlled at virtually all levels of gene regulation, due to its importance in cell cycle regulation (Bouchard et al., 1998) . In addition to message and protein having very short half-lives, c-myc transcriptional initiation and elongation control is complex (Spencer and Groudine, 1991; Marcu et al., 1992) . The c-myc gene has two primary promoters, P1 and P2, the latter accounting for B90% of c-myc message in most cells. Negative autoregulation of c-myc was first suggested by cases of c-myc-immunoglobulin translocations showing no expression of the nontranslocated myc gene (Leder et al., 1983; Mango et al., 1989) . Many studies have confirmed c-myc autorepression and generated several important observations. The property results from inhibition of initiation rather than of elongation (Grignani et al., 1990; Penn et al., 1990a) , and is lost in many transformed cells (Grignani et al., 1990) . Cells capable of autosuppression show concentration-dependent cmyc downregulation, which depends on the Myc domains also required for oncogenic cooperation with ras (Penn et al., 1990a, b) . Furthermore, the c-myc P2 promoter is involved, and interaction with the Max protein (below) also appears to be required (Facchini et al., 1997) . Nonetheless, the mechanism of Myc autorepression and necessary cis-acting promoter sequences have eluded clear definition.
Myc can activate transcription via canonical DNA binding sites -CACGTG and related -after dimerizing with the Max protein (Lu¨scher, 2001 ). Myc function is also modulated by a number of other factors, including the retinoblastoma-related p107 (Peters and Taparowsky, 1998 ). This interaction results in p107 suppression of c-Myc transactivation (Beijersbergen et al., 1994; Gu et al., 1994) . This is consistent with the transrepressive effects of Rb family proteins (Wang, 1997) , although this typically occurs by their interaction with DNAbound E2F complexes (Weintraub et al., 1992; Starostik et al., 1996) . Besides being transcriptional activators, Myc proteins also can repress transcription through start sites having initiator (Inr) elements (Li et al., 1994; Roy 2001; Wanzel et al., 2003) . Inrs have a loose consensus NPyTCAPyPyPy surrounding the underlined þ 1 A residue (Javahery et al., 1994; Smale et al., 1998) . The importance of Myc repression is underscored by c-Myc mutations unable to repress Inr-containing reporter genes also failing to cooperate in cell transformation with activated ras (Li et al., 1994 ). An B20 residue motif conserved in the Myc gene family, 'Myc Box II' (MBII), is critical for both these Myc activities (Penn et al., 1990b; Li et al., 1994) . Importantly, Myc with MBII deletions still activates genes with canonical binding sites -implying that myc þ ras cotransformation specifically requires Myc transrepression. Consistent with this, the naturally occurring 'c-Myc Short' protein (Spotts et al., 1997) , retaining MBII but lacking much of the transactivation domain, can still promote proliferation (Xiao et al., 1998) , although this varies by cell type (Hirst and Grandori, 2000) . Thus, the normal and oncogenic effects of Myc are likely mediated by two classes of target genes -those activated and those repressed by Myc (Claassen and Hann, 1999) .
Since the c-myc P2 promoter itself possesses two potential Inr motifs (Krumm et al., 1993 (Krumm et al., , 1995 , the findings discussed above raise the possibility that Myc negative autoregulation occurs by repression through such sequences. Others have of course considered this, but several mutations within the two candidate Inrs failed to affect c-Myc autosuppression (Facchini et al., 1997) . Thus the role of the c-myc P2 Inr and whether other sequences are required for autorepression remain open questions. It also remains unknown whether proteins such as p107 and the Max alternate dimerization partners (MADs) antagonize Myc repression as they do Myc transactivation. We report here that Myc autorepression requires both Inr and E2F binding sequences of the c-myc promoter. Consistent with this, Myc and p107 but not other pRb proteins cooperate in repressing c-myc, and this requires the conserved pocket domain of p107. Finally, both Myc and p107 appear to be present in a P2 gel shift complex and, most significantly, c-Myc autorepression is lost in p107-null cells.
Results
We tested c-myc promoter-reporter gene responses to exogenous c-Myc overexpression in several cell lines such as NIH3T3, CV-1, and HEK293. Although responses were similar in all, 293 cells offered technical advantages, such as consistently high transfection efficiency, high levels of P2-initiated c-myc transcripts , and established use in various assays, including c-myc promoter reporter responses Thalmeier et al., 1989) . However, we wanted to verify that 293 cells are capable of endogenous c-myc downregulation in response to exogenous Myc production. To do this, we took advantage of alternate translation start sites in the c-myc 5 0 UTR (Hann et al., 1988) . Use of these normally results in two forms of cMyc protein: p67 and p64 (Hann et al., 1988) . We transfected 293 cells with vectors expressing human cmyc having point mutations blocking use of one or the other of the translational sites, and immune precipitated c-Myc proteins from metabolically labeled cells. Figure 1a shows that overexpression of p67 causes shut-off of endogenous c-myc, seen by decrease in p64, and vice-versa. In Figure 1a , p64 downregulation by exogenous p67 is more dramatic than the reverse, but the degree of this difference is experimentally variable. Combined with RNA analyses (not shown), we conclude that 293 cells support c-myc autoregulation. Figure 1b shows the human c-myc promoter and reporter genes based on it, DP1CAT and related constructs (Krumm et al., 1995) . DP1 contains B2.5 kb of the c-myc upstream promoter minus the P1 promoter TATA box and start site, reflecting transcription solely from P2, the predominant cellular promoter (Spencer and Groudine, 1991) . We also used constructs LS5-CAT, substituting an EcoRI linker for the strong E2F site within P2, and Xho-CAT, removing most of the upstream promoter region (Figure 1b) . We wanted to verify the Myc Box II (MBII) requirement in Myc autorepression since this domain is required for Myc transrepression of other genes (Li et al., 1994) . Wild type (WT) or DMBII-Myc were transfected with either a Myc-activated reporter (M4MinCAT; Kretzner et al., 1992) or the c-myc P2 reporter (DP1CAT). Figure 1c shows representative raw data and a graph summing multiple experiments. WT and DMBII-Myc are expressed at similar levels (not shown) and both activate M4MinCAT, with four canonical Myc/Max sites (Figure 1c ), in agreement with studies of the CACGTG-containing adenovirus major late promoter (Li et al., 1994) . In contrast, the Myc P2 reporter, DP1CAT, is repressed by WT c-Myc but not DMBIIMyc (Figure 1c ). We obtained similar results using the entire c-myc promoter with P1 sequences present (not shown). It is important that DMBII-Myc loses repressive but not activating function, as it argues that P2 repression by Myc is not mediated by a Myc-activated gene product. Also note that activation of M4MinCAT by WT but not DMBII-Myc plateaus (is nonlinear), in agreement with previous studies (Kretzner et al., 1992; Li et al., 1994) . This is possibly due to an Inr-like sequence at the MinCAT start site (CCTCGACACC, þ 1 bold). We tested the autorepression requirements for other conserved Myc domains in our system (not shown), finding as others (Penn et al., 1990b) that the bHLH-Zip domain and an intact N-terminus are critical. We also found (not shown) that Mxi1 -but not Mads 1, 3, or 4 -has a modest but consistent repressive effect on c-myc P2, as seen before (Lee and Ziff, 1999) . Mxi1 represses less well than c-Myc ( Figure 2b ) and gives no additive effect upon coexpression. Thus, as detailed above, our system for studying cmyc promoter regulation, including autorepression, is very comparable to others previously used.
Promoter sequences required for c-myc autorepression
The results of Li et al. (1994) suggested that c-myc autorepression would map to the P2 Inr. Consistent with this, Myc autoregulation requires the Box II domain (Figure 1c ) (Facchini et al., 1997) . Myc also represses smaller P2 'core' reporters such as Xho-CAT, c-Myc autorepression via Inr þ E2F sites Q Luo et al as well as full-length constructs. However, Facchini et al. (1997) tested several mutations at the P2 start site Inr and in another potential downstream Inr, and found that c-Myc still represses these. Nonetheless, to extend that data we made and tested novel point mutations in the P2 start site Inr. Using the WT human c-myc promoter and primers A and D, we generated P2minWT-CAT (Figure 2a) , which is repressed as well or better than the longer reporter, DP1CAT (Figure 2b ). The 'core two' (C2M) and 'flanking three' (F3M) mutations were then introduced into the P2minWT initiator element (Figure 2a ). Figure 2b shows that these additional Inr mutations have little effect on c-Myc or Mxi1 repression. Our data and that of Facchini et al. (1997) together show that Myc autosuppression does not map simply to the P2 Inr. Although repression by WT c-Myc in most of these experiments is 2-3-fold, it is statistically significant with sufficient replications (Figures 2b and 4a) . The degree of c-Myc repression of the C/EBPa and albumin reporters was similarly in the 2.5-3 Â range (Li et al., 1994) , as is c-Myc activation of reporter genes in most systems (Amati et al., 1992; Kretzner et al., 1992; Grandori et al., 1996; Spotts et al., 1997) .
We next analysed other transcription factor binding sites within the P2 core. Prominent among these are the conserved and well-characterized E2F binding sites at À60 and À35 (Thalmeier et al., 1989; Dagnino et al., 0 to those previously documented is indicated by question mark. Construct used in most experiments, unless otherwise noted, is DP1-CAT, the 2.5 kb c-myc promoter with P1 TATA box and start site deleted (nucleotides À189 to À160). All nucleotide positions numbered relative to P2 start site as defined by Krumm et al. (1993 Krumm et al. ( , 1995 . In addition to the putative initiator element (Inr) surrounding start site as defined here, a second potential Inr (and start site as defined in Facchini et al., 1997) is indicated as Inr2. Linker-scanner 5 (LS5-CAT) replaces six base pairs of the highest affinity E2F/ETS site (Thalmeier et al., 1989) with an EcoRI site. Xho-CAT is WT human c-myc P2 core promoter truncated at XhoI site. (c) Contrasting effects of WT and DMBII-Myc on activatable vs cmyc P2 promoter reporters. Upper panel shows sample result and lower panel summarizes multiple experiments. 293 cells were transfected with the indicated amounts of WT or DMBII-Myc expression vectors with 3 mg of either canonical Myc-activated reporter, M4MinCAT (Kretzner et al., 1992) , or 3 mg of the c-myc P2 promoter reporter, DP1CAT. Standard CAT assays normalized to transfection efficiencies were performed (Materials and methods). In this and similar figures comparing multiple reporters, the 'fold' basal activity of a given reporter in the presence of empty vector (RCMV, i.e., pRc/CMV) is set to 1 Â . The average activity of a reporter at this reference level is given in c.p.m. within the clear (vector only) bar of each data set, showing in this case for example that the basal activity level of the synthetic minimal M4MinCAT promoter is lower than that of the 2.5-kb c-myc promoter c-Myc autorepression via Inr þ E2F sites Q Luo et al 1995). E2F complexes bound to these can serve as 'docking sites' for pRb family transcriptional repressors (Weintraub et al., 1992; Starostik et al., 1996) . The Rbrelated p107 can also interact with c-Myc to inhibit transactivation (Beijersbergen et al., 1994; Gu et al., 1994) . We therefore tested c-Myc repression of c-myc reporters with E2F site mutations. We found normal downregulation from linker-scanner mutation LS5-CAT (Figure 1b) , bearing an EcoRI sequence in place of the highest affinity E2F site at -60. We thus wanted to narrow potential cis-acting autosuppression sequences and eliminate all possible E2F binding sites, including that at À35 and a potentially cryptic site from À13 to -8 (CGGGGC). We used another linker-scanner mutation, LS12 (À16 to À11), plus a PCR primer downstream of the known E2F sites to generate DE2F-CAT (Figure 2a) , devoid of E2F sites. This construct is downregulated a bit less well than WT or Inr mutation reporters, suggesting some possible importance of E2F sites for Myc autorepression. Mindful of interaction between p107 and Myc (Beijersbergen et al., 1994; Gu et al., 1994) and the transrepressive nature of Rb family proteins (Hamel et al., 1992; Starostik et al., 1996) , we hypothesized that a p107/Myc interaction might circumvent the effects of single Inr and E2F mutations. In this case a combined E2F þ Inr mutation might downregulate poorly or not at all. We made and tested such a construct, DE2F/F3M-CAT, and the last set of bars in Figure 2c shows that neither c-Myc nor Mxi1 represses this double mutation. Thus, either an intact Inr or E2F site allows essentially normal levels of Myc autorepression, but downregulation is completely lost when both sites are mutated. These data define for the first time specific sequences required for c-Myc autorepression, making it clear that both intact Inr and E2F binding sites are necessary.
Role of p107 in repression of the c-myc promoter
The results summarized in Figure 2c warranted further analysis of p107 and other Rb proteins' effects on the cmyc promoter, particularly in the presence of Myc. A priori, p107 could be a general Myc antagonist, interfering with repression as well as activation (Beijersbergen et al., 1994; Gu et al., 1994) . A more likely alternative is that p107 acts as a general transcriptional repressor and thus might actually augment Myc autorepression. We first determined that p107 as well as Mxi1 repress endogenous c-myc in 293 cells (Figure 3a ). We then directly tested the effect of p107 expression on Myc autorepression, and Figure 3b shows that p107 and c-Myc repress DP1CAT both individually and synergistically (third and fourth CAT lanes with Myc and p107, vs fifth and sixth lanes with p107 alone). Thus, p107 acts as a general repressor, not a general Myc antagonist, and augments Myc autorepression. We then tested each pRb family gene for c-myc repression, either with or without Myc or Mxi1. Figure 3c shows their effects plus that of anti-sense p107 (AS-p107). Rb genes were tested cotransfecting vector alone (columns 1-5), c-Myc (columns 6-10), or Mxi1 expression vectors columns 11-15) . The data show that p107 has the strongest repressive effect on the c-myc reporter (column 2 vs 3-5), and that only p107, not pRb or p130, augments c-Myc repression of DP1CAT (column 7 vs 8-10). There was no additive effect of p107 and Mxi1 in these experiments (column 2 vs 12). Nonetheless, consistent with strong p107 repression, AS-p107 interfered with both Myc (column 6 vs 11) and Mxi1 repression (column 10 vs 15). We obtained similar results in primary rat embryo fibroblasts (not shown). Thus, within the pRb family, only p107 cooperates with c-myc autorepression.
We next tested p107 effects on c-myc core promoter mutations. Figure 4a shows that p107 represses the WT and Inr mutations and also the E2F deletion/mutation construct, DE2F-CAT, but not the double mutation of E2F plus Inr sites, DE2F/F3M-CAT (Figure 4a) . Thus, c-myc promoter mutations respond similarly to Myc and p107. The Inr þ E2F doubly mutated reporter cannot be downregulated by Myc, Mxi1, or p107, while mutations in Inr or E2F sites alone behave essentially the same as WT reporters (Figures 2c and 4a) . While initially surprising, p107 repression of a c-myc promoter lacking E2F sites was reported before (Dagnino et al., 1995) . We nonetheless wanted to be absolutely sure that our vector did not contain cryptic E2F sites. This was tested and ruled out in two ways (not shown). First, p107 does not repress reporters with the same vector 'backbone' as DP1CAT (i.e., MinCAT and M4MinCAT; Kretzner et al., 1992) . Second, expression of a dominant-negative E2F partner, DP1-D127, which interferes with endogenous E2F binding (Wu et al., 1996) , had no effect on p107 or Myc repression of our reporters. We thus agree with Dagnino et al. (1995) that p107 can repress c-myc independently of E2F sites. The authors suggested p107 interacts with other promoter-binding factors besides E2F to effect repression, and we further suggest that these may include Myc itself (Figure 6 and Discussion).
To further test putative p107 cooperation with Myc in autorepression, we attenuated p107 levels in several P-labeled antisense transcript of the C-terminal 186 coding nucleotides of c-myc plus nonprotected polylinker, and human cyclophillin probe was similarly made using in vitro transcription template (RPA II, Ambion). Levels of endogenous c-myc, relative to the cyclophillin control, were: RCMV ¼ 100%, p107 ¼ 38%, and Mxi1 ¼ 65%, by densitometry. (b) Sample CAT assay showing p107 and Myc effects on DP1CAT. Basal activity of DP1CAT is seen in the first lane; 3 mg c-Myc was added to cells used in lanes 2-4; p107 was added in amounts indicated to cells used in lanes 3-6. The middle two lanes thus show p107 þ Myc synergy. As in all experiments, the total amount of DNA added was held constant by addition of empty vector as necessary. (c) Summary of results showing that p107, but not pRb or p130, strongly represses c-myc reporter and potentiates c-Myc repressive effects. In all, 4 mg c-myc or Mxi1 expression plasmids was transfected together with either 2 mg pRc/CMV (vector) or 2 mg each of CMV-driven pRb family genes indicated. AS-p107 ¼ anti-sense p107 expression construct c-Myc autorepression via Inr þ E2F sites Q Luo et al ways, including AS-p107 expression as above (Figure 3c ). We also tested the effect of E1A -known to sequester and inactivate pRb proteins -on c-myc repression by Myc, Mxi1, and p107, and all three were indeed antagonized (data not shown). Next we tested a well-characterized p107 deletion mutant, p107DDE (Zhu et al., 1993) , lacking the conserved 'pocket domain' of p107 that is necessary and sufficient for full p107-Myc and p107-E2F interaction (Beijersbergen et al., 1994; Gu et al., 1994; Zhu et al., 1995) . We tested p107DDE with three P2 promoter variants, and Figure 4b shows that it indeed represses the intact P2 promoter less well than WT p107. We suggest the partial repression of WT Inr c-myc reporters by p107DDE (DP1 and P2minWT, Figure 4b ) is likely due to residual Myc binding of this p107 mutant (not shown; Beijersbergen et al., 1994) . Most strikingly, however, p107DDE cannot repress the c-myc promoter Inr mutation, F3M -a strong parallel to the data obtained using double mutations in E2F and Inr sites (Figures 2c and 4a ). To test directly p107's importance in Myc autorepression, we compared repression of murine c-myc by human Myc in p107-null mouse embryo fibroblasts (MEFs) to that in WT MEFs from isogenic littermates (Hurford et al., 1997) . Human and rodent c-myc promoters are well conserved overall including P2 Inr and E2F binding sites (Thalmeier et al., 1989; Penn et al., 1990a) . Figure 5a shows endogenous c-myc message levels of WT and Lastly, to find direct physical evidence for the presence of c-Myc and p107 at the c-myc core promoter, we ran electrophoretic mobility shift assays (EMSA) using cellular extracts from control 293 cells vs those overexpressing c-Myc and p107. PCR-generated probes consisted of the c-myc P2 core promoter including the TATA box and Inr (À31 to þ 15). We tried many protocols for cell or nuclear lysates, plus variations in binding and gel conditions, most to no avail. That of Sonenshein and colleagues (Yang et al., 2001 ) was the only method giving clear, reproducible results. Figure 5b shows that P2 probe binding is greater with lysates from cells overexpressing c-Myc and p107 (lane 3 vs lane 2). Most significantly, both anti-Myc and anti-p107 antibodies affect the higher mobility complex (lanes 4 and 5 vs lane 3). Little if any supershift is visible with anti-Myc Ab, but it interferes with complex formation (lane 4 vs lane 3, Myc-p107 band). Anti-p107 Ab gives a clear supershift and diminishes the intensity of the original higher mobility band (lane 5), which we interpret as a complex containing p107 and c-Myc. Binding by Myc clearly appears weaker than that by p107, and indeed most Myc-Inr interactions studied thus far suggest that Myc binding is indirect (reviewed in Wanzel et al., 2003) . The results in Figure 5a and b taken together with our other data strongly argue that Myc autorepression operates through both Inr and E2F sites, and indicate that p107 plays an essential role in this repression.
Discussion
The most notable findings of this study show that Myc autoregulation requires both c-myc promoter Inr and E2F binding elements, and demonstrate the importance of p107 in autosuppression. The importance of Myc Box II and the P2 Inr element in autoregulation was predicted based on Myc repression of other genes (Li et al., 1994) . While MBII is indeed required, P2 Inr mutations do not block Myc repression, and we thus tested the role of E2F sites. This was also prompted by considering p107 interactions with E2F and Myc (Beijersbergen et al., 1994; Gu et al., 1994) , conserved c-myc promoter E2F sites (Thalmeier et al., 1989) , and transrepression by Rb genes (Hamel et al., 1992; Starostik et al., 1996) . Constructs lacking all E2F sites were repressed just slightly less well than comparable WT promoters. Only the reporter lacking both E2F and normal Inr sites cannot be repressed by Myc, demonstrating a joint requirement for these elements. The coinvolvement of E2F sites in autorepression led to testing the effects of pRb family genes. The data make clear that p107 augments Myc repression while pRb and p130 gene products do not, and that c-myc repression by p107 -like that by Myc itself -requires both E2F and Inr sites. The first point likely reflects interaction between Myc and p107, which pRb and p130 lack. More surprisingly, a promoter lacking E2F sites was downregulated by Myc, Mxi1, and p107. We show that p107 represses a c-myc promoter lacking E2F sites, as seen before (Dagnino et al., 1995) , but not one lacking both E2F and Inr sites (Figure 4a ). These data confirm and extend the previously unexplained observations of Dagnino et al. (1995) . The joint involvement of E2F and Inr elements, and of p107 and Myc, suggested testing a p107 pocket domain deletion. This mutation indeed interferes with p107's ability to repress P2, especially when P2 carries a mutant Inr. While all Rb genes typically function as transrepressors (Hamel et al., 1992; Starostik et al., 1996; Wade, 2001) , we suggest that the specific interaction of c-Myc and p107 allows the latter protein to play a critical role in c-myc autorepression. Consistent with this, and significantly, we show here that exogenous Myc cannot repress murine c-myc in p107-null cells. Figure 6 shows one possible model fitting these data. A p107/Myc interaction with the core promoter is likely through other proteins, for example, p107 via E2F proteins, and Myc perhaps via candidate Inr-binding proteins such as TFII-I (Roy, 2001 ), Miz1 (Wanzel et al., 2003) , or SP-1 (Gartel et al., 2001) . We speculate that cMyc and p107 interact cooperatively at the c-myc promoter through these and/or other factors (Figure 6 , top). With either single mutation (Inr or E2F), a p107/ Myc complex may still be recruited to repress the P2 reporter. When Inr interactions are weak, the complex may assemble via intact E2F sites, and vice versa (Figure 6 , bottom left and center). This is supported by Myc, Mxi1, and p107 repressing either of the single Inr or E2F mutations but not the doubly mutated E2F þ Inr sites ( Figure 6 , bottom right). The model symbolically depicts repression (curved line and bar) coming directly from p107, although repression by the Rb family is typically mediated by cofactors not shown, such as histone deacetylases (Wade, 2001 ). In any case, Figure 6 remain speculative without more detailed knowledge of how Myc interacts with the Inr, but p107 interactions with E2F and c-Myc are well supported, and the model is consistent with our data. The observation that p107 augments Myc autorepression raises the question of how general a phenomenon this may be in other cases of Myc repression. Mutating some Inrs suffices to block Myc repression (Li et al., 1994) , and since this is not so at the c-myc promoter itself, Myc autoregulation may represent a special case of Myc repression. However the similarity between the c-myc promoter and those of several other genes (Krumm et al., 1993) suggests that a subset of Inrcontaining promoters may be repressed by Myc in cooperation with p107, especially given Inr variability (Smale et al., 1998) . Additionally, our own and previous data ( Figure 4a ; Dagnino et al., 1995) suggest that p107 þ Myc repression may occur at promoters not bearing canonical E2F sites. Further experiments assessing p107's role in other cases of Myc repression are certainly warranted, since this aspect of c-Myc is closely tied to its oncogenic potential (Claassen and Hann, 1999; Wanzel et al., 2003) .
Materials and methods

Plasmids
Reporter genes Full-length WT (2.5 kb, HindIII-NaeI), DP1, and linker-scanner (LS) EcoRI substitutions of the human cmyc promoter ( Figure 1a) were from Anton Krumm and Mark Groudine (Krumm et al., 1995) . The 5 0 HindIII and 3 0 NaeI sites of c-myc were blunted and linked to blunted vector BglII sites of pGL-CAT3. Xho-CAT was made by digesting DP1CAT with HindIII and XhoI, blunt ending, and re-ligation. Core P2 promoter constructs were made by PCR amplification of the human c-myc promoter regions noted in Figure 2a with the primers below. Numbers in parentheses are 3 0 nucleotides of each primer and indicate positions in the c-myc promoter relative to the P2 start site. Upstream primers:
. PCR products were cut with enzymes in italics above, gel purified, and ligated to pGL-CAT3 similarly cut. The WT core promoter, P2minWT, was made using primers A and D with DP1CAT as template, then cloning into the PstI and XhoI sites of pGL-CAT3. The core promoter lacking all possible E2F sites, DE2F, was generated similarly using primers B and C with c-myc template being the LS12 EcoRI linker insertion at À16 to À11 of P2 (Krumm et al., 1995) . Inr mutations C2M and F3M were made by the 'Quick Change' mutatgenesis procedure (Stratagene). Primers corresponding to mutant sequences in Figure 2a were used, with either P2minWT or DE2F c-myc DNAs as templates. All constructs were sequence verified.
Expression vectors SV40-driven Myc, Max, and Mad vectors were described before (Kretzner et al., 1992; Ayer et al., 1993; Hurlin et al., 1995) . These genes were removed with HindIII þ XbaI, gel purified, and subcloned into the pRc/ CMV vector (Invitrogen) similarly cut. Lin-heng Li and Ed Ziff provided DMBII-Myc (Li et al., 1994) , which we similarly subcloned into pRc/CMV. Kevin Foley and Bob Eisenman supplied CMV-Mxi1-SR. CMV-driven p107 and p107 deletions (Wu et al., 1996) were from Liang Zhu. Jackie Bruce and Nick Dyson provided p130 (Hurford et al., 1997) .
Cell culture and transfections
All cells were grown in DMEM þ 10% fetal calf serum and antibiotics. Cells were split to B5 Â 10 5 cells/10 cm plate 1 day pretransfection and refed 2-3 h pretransfection. Most transfections were by standard calcium phosphate, with plasmid amounts indicated in figures or figure legends. Total DNA was always held constant with empty vector. Lipofection was used with cells meant for RNA extraction, using Lipofectamine (Life Sciences). After overnight transfections, cells were washed once with warm 1 Â HEPES-NK (10 mM HEPES (pH 7.3), 0.142 M NaCl, 6.7 mM KCl), refed fresh medium, and harvested B30 h later with gentle pelleting in 1 ml TEN (40 mM Tris (pH 7.4), 1 mM EDTA, 150 mM NaCl). Cell pellets resuspended in 100 ml 0.25 M Tris (pH 7.8) were frozen at À801C.
Reporter gene assays, viral infections, and RNA analysis CAT assays were as described (Kretzner et al., 1992) . Typically, 5-15 mg 293 cell lysate was used in b-gal and CAT assays, with final volumes of the latter adjusted by transfection efficiencies determined by the former. For spotted assays, 14 Cchloramphenicol (Amersham) and 10 mM acetyl CoA (Pharmacia) were substrates in 1 h reactions at 371C. Reactions were ethyl acetate extracted, dried, spotted on TLC plates in 12 ml of ethyl acetate, and run 1 h in 95 : 5 CHCl 3 : MeOH. Plates were dried and quantified with PhosphorImager (Molecular Dynamics). For direct scintillation-quantified assays, 3 H-AcCoA (ICN) and 10 mM chloramphenicol (Pharmacia) were used; otherwise, assays were as above. Absolute CAT activity of reference lysates (empty vector transfectants) varied from 6000 to 27 000 c.p.m., remaining within the assay linear range (nonacetylated substrate in excess) in all experiments. Results were converted to 'fold' effects, defining reference lysate activity as 1 Â . N-value with each graph ¼ number of individual transfections. Data were statistically analysed by factorial ANOVA with post hoc Bonferroni/Dunn analysis. The data in Figures 2c and 4a are from the same set of experiments, but are separated in the text for clarity.
RNA was extracted with 'Totally RNA' reagents (Ambion) or TRI-REAGENT (Sigma). In all RPAs, 4 mg of RNA was hybridized with B8000 c.p.m. probe in 20 ml hybridization buffer (Ambion) at 481C overnight. Hybridized RNA was digested by RNases A þ T (RPA II, Ambion) and precipitated. Protected RNAs were run on 6% denaturing polyacrylamide gels. Probes are described in figure legends. Viral infections: WT and syngeneic p107-null MEFs, a gift of Drs Fred Dick and Nick Dyson (Wu et al., 1996; Hurford et al., 1997) , were infected with high-titer LXSN retroviral supernatant made in C2 ecotrophic packaging cells (Miller et al., 1993) , using 4 mg/ ml polybrene. Cells were harvested 36 h postinfection and RNA prepared.
Electrophoretic mobility shift assay
Nuclear extracts of control 293 cells and those cotransfected with c-myc and p107 (in Rc/CMV) were made as described (Yang et al., 2001 ) with modification as follows. In all, 1-c-Myc autorepression via Inr þ E2F sites Q Luo et al 2 Â 10 8 cells were gently centrifuged and resuspended in 1 ml (five packed cell volumes) buffer A for 15 min. Swollen cells were recentrifuged, resuspended in 400 ml cold buffer A, and lysed by NP-40 at 0.4% (vol/vol) and vortexing. Crude nuclei were resuspended in 300 ml cold buffer C by passing up and down five times through a 22-guage needle with a 1 ml syringe. This suspension was incubated for 30 min at 41C on a 20 r.p.m. vertical spinner. After 30 min centrifugation at 16 000 g and 41C, the supernatant was microdialysed against two changes of 25 ml buffer D for 2 h each at 41C. After a final 16 000 g spin for 15 min at 41C, B250 ml of dialysate (final nuclear extract) was collected from control and transfected cells. Any buffers or steps not specified above were as in Yang et al. (2001) , as were binding reactions. Nuclear extract (5 mg) was incubated for 40 min at room temperature with 20 000 c.p.m.
32 P-labeled c-myc initiator probe (below) before gel loading. For supershift assays, 5 mg nuclear extract was incubated for 30 min on ice with 1 mg antibody specific for c-Myc or p107 (Santa Cruz Biotechnology, Inc.) prior to probe addition. Binding reactions were run on 4% nondenaturing polyacrylamide gels (Yang et al., 2001) . The PCR Core Kit (Roche) was used to amplify and label human c-myc P2 TATA þ initiator from 200 ng DP1CAT.
Reactions (50 ml) contained 1 mM forward and reverse primers (primers B and C, above), 0.2 mM dNTP, 1.5 mM MgCl 2 , 2 ml of 10 mCi/ml 32 P-a-dCTP, and 1 ml Taq polymerase. Cycling program: 951C for 5 min, followed by 31 cycles of 941C/20 s, 561C/30 s, and 721C/40 s. Final extension was for 5 min at 721C. Probe was purified with sepharose Quick Spin TM Column (Boeringer Mannheim).
